journal
Journals Cost Effectiveness and Resourc...

Cost Effectiveness and Resource Allocation : C/E

https://read.qxmd.com/read/38291507/a-new-innovative-method-to-measure-the-cost-of-war-future-with-fewer-conflicts-via-harm-reduction-approaches
#21
JOURNAL ARTICLE
Ehsan Jozaghi
BACKGROUND: The destruction of World War I (WWI) and World War II (WWII) changed the world forever. In this analysis, the economic costs of WWI and WWII are considered via a harm reduction approach to highlight the cost of war via the mortality of military personnel. The harm reduction philosophy and homeostasis of a biological cell are utilized as a pragmatic approach and analogy to give a greater context to the findings, despite the omission of civilian casualties and military disabilities...
January 30, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38291472/preferences-as-fairness-judgments-a-critical-review-of-normative-frameworks-of-preference-elicitation-and-development-of-an-alternative-based-on-constitutional-economics
#22
REVIEW
Wolf Rogowski, Jürgen John
Preference elicitation is widely used within health economic evaluations to inform coverage decisions. However, coverage decisions involve questions of social justice and it is unclear what role empirical evidence about preferences can play here. This study reviews the prevalent normative frameworks for using population-based preference elicitation and the criticisms they face, and proposes an alternative based on constitutional economics. The frameworks reviewed include a supposedly value-neutral framework of preferences as predictors of choice, preference utilitarian frameworks that aim to maximize preference satisfaction, and substantive consequentialist frameworks that aim to maximize happiness, health, or capabilities...
January 30, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38281053/a-cost-effectiveness-analysis-of-the-combination-of-serplulimab-with-chemotherapy-for-advanced-esophageal-squamous-cell-carcinoma-insights-from-the-astrum-007-trial
#23
JOURNAL ARTICLE
Jiahui Li, Chaoqun Xu, Suyun Yuan
BACKGROUND: Combined serplulimab and chemotherapy demonstrated improved clinical survival outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) and PD-L1 combined positive scores (CPS) ≥ 1. The present study aimed to evaluate the economic viability of integrating serplulimab in combination with chemotherapy as a potential therapeutic approach for treating ESCC in China. METHODS: A Markov model was constructed to evaluate the economic and health-related implications of combining serplulimab with chemotherapy...
January 27, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38268008/retention-of-the-highly-educated-migrants-from-the-perspective-of-urban-e-service-capability
#24
JOURNAL ARTICLE
Fan Zhaoyuan, Liu Xiaofeng
BACKGROUND: Talent is a crucial resource for economic and social development, serving as the driving force behind urban progress. As China experiences rapid growth in digital city construction, the capability of e-services continues to improve incessantly. In China, the new-generation highly educated migrants (NGHEMs) account for ~ 20-30% of the total floating populations. This study aimed to explore the settlement intention of new-generation highly educated migrations in China from the new perspective of urban e-service capabilities...
January 24, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38267990/cost-effectiveness-of-pembrolizumab-versus-chemotherapy-in-patients-with-platinum-pretreated-recurrent-or-metastatic-nasopharyngeal-cancer
#25
JOURNAL ARTICLE
Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu
BACKGROUND: Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC). We aimed to assess the cost-effectiveness of pembrolizumab compared with chemotherapy for Chinese patients in this NPC. METHODS: The cost-effectiveness of pembrolizumab versus chemotherapy was evaluated using a partitioned survival model with a 5-year boundary. Efficacy and toxicity data were derived from the KEYNOTE-122 trials...
January 24, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38263043/reimagining-the-relationship-between-economics-and-health-who-health-for-all-provisions
#26
EDITORIAL
Stavros Petrou, Mihajlo Jakovljevic
No abstract text is available yet for this article.
January 23, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38238836/cost-utility-of-tiotropium-in-patients-with-severe-asthma
#27
JOURNAL ARTICLE
Jefferson Antonio Buendía, Diana Guerrero Patiño
UNLABELLED: Add-on therapy with tiotropium was cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA in a middle-income country. BACKGROUND: A significant proportion of asthma patients remain uncontrolled despite inhaled corticosteroids and long-acting beta-agonists. Some add-on therapies, such as tiotropium bromide, have been recommended for this subgroup of patients. This study aimed to assess the cost-effectiveness of tiotropium as an add-on therapy to inhaled corticosteroids and long-acting b2 agonists for patients with severe asthma...
January 18, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38238797/cost-of-illness-studies-in-covid-19-a-scoping-review
#28
REVIEW
Majid Nakhaee, Masoud Khandehroo, Reza Esmaeili
BACKGROUND: Human communities suffered a vast socioeconomic burden in dealing with the pandemic of coronavirus disease 2019 (COVID-19) globally. Real-word data about these burdens can inform governments about evidence-based resource allocation and prioritization. The aim of this scoping review was to map the cost-of-illness (CoI) studies associated with COVID-19. METHODS: This scoping review was conducted from January 2019 to December 2021. We searched cost-of-illness papers published in English within Web of Sciences, PubMed, Google Scholar, Scopus, Science Direct and ProQuest...
January 18, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38195603/mitigating-role-of-financial-inclusion-on-the-perceived-difficulties-concerns-and-borrowing-for-medical-expenses-in-saudi-arabia
#29
JOURNAL ARTICLE
Mohammed Khaled Al-Hanawi, Naseem Al Rahahleh
Access to convenient quality healthcare at all times is considered a basic human right; however, many countries are still striving to achieve this goal for their populations. The persistent rise in healthcare expenditure remains a significant obstacle in achieving universal health coverage on a global scale. The aim of this study was to investigate the role of financial inclusion in addressing the financial hardship related to health and medical expense concerns in the Kingdom of Saudi Arabia. Probit models were applied to analyse nationally representative data from the Global Financial Inclusion (Global Findex) database...
January 9, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38178078/investing-in-midwifery-for-sustainable-development-goals-in-low-and-middle-income-countries-a-cost-benefit-analysis
#30
JOURNAL ARTICLE
Chakib Boukhalfa, Brahim Ouakhzan, Hanane Masbah, Leila Acharai, Saad Zbiri
BACKGROUND: Maternal and neonatal mortality in low- and middle-income countries is frequently caused by inadequate management of obstetric and neonatal complications and a shortage of skilled health workers. The availability of these workers is essential for effective and high-quality healthcare. To meet the needs of sexual, reproductive, maternal, new-born, child, and adolescent health by 2030, more than one million health workers, including 900 000 midwives, are required globally. Despite this, uncertainty persists regarding the return on investment in the health workforce...
January 4, 2024: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38115117/population-ageing-and-sustainability-of-healthcare-financing-in-china
#31
REVIEW
Wenqing Wu, Shujie Long, Arcadio A Cerda, Leidy Y Garcia, Mihajlo Jakovljevic
BACKGROUND: In China, the healthcare financing structure involves multiple parties, including the government, society and individuals. Medicare Fund is an important way for the Government and society to reduce the burden of individual medical costs. However, with the aging of the population, the demand of Medicare Fund is increasing. Therefore, it is necessary to explore the sustainability of the healthcare financing structure in the context of population ageing. OBJECTIVE: The purpose of this paper is to organize the characteristics of population ageing as well as healthcare financing in China...
December 19, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38102674/resource-allocation-in-public-sector-programmes-does-the-value-of-a-life-differ-between-governmental-departments
#32
JOURNAL ARTICLE
Patricia Cubi-Molla, David Mott, Nadine Henderson, Bernarda Zamora, Mendel Grobler, Martina Garau
BACKGROUND: The value of a life is regularly monetised by government departments for informing resource allocation. Guidance documents indicate how economic evaluation should be conducted, often specifying precise values for different impacts. However, we find different values of life and health are used in analyses by departments within the same government despite commonality in desired outcomes. This creates potential inconsistencies in considering trade-offs within a broader public sector spending budget...
December 15, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38071302/comparative-effectiveness-and-cost-evaluation-of-risankizumab-and-adalimumab-in-the-management-of-psoriasis-a-real-world-study-in-saudi-arabia
#33
JOURNAL ARTICLE
Yazed AlRuthia, Almaha H Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh, Majed Ali Almasaoud
BACKGROUND: Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most common. Treatment, which has no definitive cure, aims for complete resolution of skin symptoms and depends on disease extent, severity, and impact on patients' lives. Biologics are an emerging treatment for psoriasis, targeting specific inflammatory pathways for potentially safer, more effective outcomes...
December 9, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38066603/cost-analysis-of-the-management-of-end-stage-renal-disease-patients-in-abuja-nigeria
#34
JOURNAL ARTICLE
Yakubu Adole Agada-Amade, Daniel Chukwuemeka Ogbuabor, Ejemai Eboreime, Obinna Emmanuel Onwujekwe
BACKGROUND: Although the treatment for end-stage renal disease (ESRD) under Nigeria's National Health Insurance Authority is haemodialysis (HD), the cost of managing ESRD is understudied in Nigeria. Therefore, this study estimated the provider and patient direct costs of haemodialysis and managing ESRD in Abuja, Nigeria. METHOD: The study was a cross-sectional survey from both healthcare provider and consumer perspectives. We collected data from public and private tertiary hospitals (n = 6) and ESRD patients (n = 230) receiving haemodialysis in the selected hospitals...
December 8, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38041072/methodology-and-results-of-cost-effectiveness-of-ldl-c-lowering-with-evolocumab-in-patients-with-acute-myocardial-infarction-in-china
#35
JOURNAL ARTICLE
Yuansheng Wan, Jinyu Liu, Xiaolian Zhan, Yu Zhang, Ruxu You
BACKGROUND: According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease. However, because of the variation in the price of evolocumab and its different methods of confirming clinical efficacy, it was necessary to explore its economics and the impact of different methods of confirming efficacy on its economic studies. OBJECTIVE: The purpose of this paper was to assess the cost-effectiveness of evolocumab with statins versus statins alone for patients with acute myocardial infarction(AMI) in China and to investigate the impact of different clinical effectiveness modeling approaches on economic outcomes...
December 1, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38037138/a-systematic-literature-review-on-direct-and-indirect-costs-of-triple-negative-breast-cancer
#36
REVIEW
Sadeq Rezaei, Majid Babaei
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive and therapy-resistant form of breast cancer with a significant economic burden on patients and healthcare systems. Therefore, we completed a systematic review to classify and synthesize the literature on the direct and indirect costs of TNBC. METHODS: Databases including ISI Web of Science, Scopus, PubMed, and Google Scholar were searched for all related articles assessing the economic burden of TNBC from 2010 until December 2022...
November 30, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38012661/cost-effectiveness-of-abemaciclib-plus-endocrine-therapy-in-high-risk-hr-her2-early-breast-cancer-in-china
#37
JOURNAL ARTICLE
Qiran Wei, YuTing Xu, Wei Liu, Xin Guan
OBJECTIVE: The aim of this article is to evaluate the cost-effectiveness of abemaciclib plus endocrine therapy (ABE + ET) vs. ET as adjuvant treatment for high-risk hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer in China. METHODS: From the perspective of the Chinese health care system, a 5-state Markov model was developed with a lifetime horizon. Data of the monarchE phase III clinical trial were used to model the invasive disease-free survival (iDFS) and standard parameters models were used for data extrapolation...
November 27, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38007522/health-system-productivity-in-sub-saharan-africa-tuberculosis-control-in-high-burden-countries
#38
JOURNAL ARTICLE
Esso-Hanam Atake
BACKGROUND: Sixteen of the 30 countries with a high tuberculosis (TB) burden are in Sub-Saharan Africa (SSA). Over 25% of TB deaths occur in the Africa region. This study aims to estimate the productivity changes of TB programs in 16 SSA countries where TB is endemic. METHODS: We used Hicks-Moorsteen index to compute and decompose Total factor productivity (TFP), and the β-convergence and σ-convergence tests to check for convergence patterns among SSA countries...
November 25, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/37990328/factor-associated-with-willingness-to-pay-for-prevention-of-cancer-a-study-of-prostate-cancer-screening
#39
JOURNAL ARTICLE
Hiro Farabi, Najmeh Moradi, Aziz Ahmadzadeh, Seyed Mohammad Kazem Agamir, Abdolreza Mohammadi, Aziz Rezapour
INTRODUCTION: This study investigates Iranian men's willingness to pay (WTP) for prostate cancer (PCa) screening and influencing factor, along with the impact of information. METHOD: We assessed preferences for prostate cancer screening in 771 Iranian men aged 40 and above using an internet-based questionnaire survey. Participants received basic and complementary information, and their willingness to pay was determined through a payment card approach. A Wilcoxon test assessed the impact of information...
November 21, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/37986000/cost-effectiveness-of-implant-movement-analysis-in-aseptic-loosening-after-hip-replacement-a-health-economic-model
#40
JOURNAL ARTICLE
Davide Lovera, Olof Sandberg, Maziar Mohaddes, Hanna Gyllensten
OBJECTIVE: To investigate the cost-effectiveness of using Implant Movement Analysis (IMA) to follow up suspected aseptic loosening when the diagnosis after an initial X-ray is not conclusive, compared with a diagnostic pathway with X-ray follow-up. METHODS: A health-economic model in the form of a decision tree was developed using quality-adjusted life years (QALY) from the literature, cost-per-patient data from a university hospital and the probabilities of different events from expert physicians' opinions...
November 20, 2023: Cost Effectiveness and Resource Allocation: C/E
journal
journal
40406
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.